Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filling bone erosions: subcutaneous tocilizumab in rheumatoid arthritis
2024-517686-17-01Phase 4Authorised
- Sponsor
- CHU d'Orléans
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by CHU d'Orléans. Primary endpoint: Change in bone erosion dimensions by HR-pQCT. Planned start Jan 2025; status: authorised.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-517686-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517686-17-01.